National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Bladder and Other Urothelial Cancers Screening (PDQ®)     
Last Modified: 03/13/2008
Health Professional Version
Overview

Benefits
Harms

Note: Separate PDQ summaries on Bladder Cancer Treatment 1 and Levels of Evidence for Cancer Screening and Prevention Studies 2 are also available.

Benefits

There is inadequate evidence to determine whether screening for bladder and other urothelial cancers has an impact on mortality.

Description of the Evidence

  • Study Design: There are no studies that directly address this question.
  • Internal Validity: N/A.
  • Consistency: N/A.
  • Magnitude of Effects on Health Outcomes: N/A.
  • External Validity: N/A.
Harms

Based on fair evidence, screening for bladder and other urothelial cancers would result in unnecessary diagnostic procedures with attendant morbidity.

Description of the Evidence

  • Study Design: Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.
  • Internal Validity: N/A.
  • Consistency: N/A.
  • Magnitude of Effects on Health Outcomes: Good evidence for rare harms.
  • External Validity: N/A.


Table of Links

1http://cancer.gov/cancertopics/pdq/treatment/bladder/HealthProfessional
2http://cancer.gov/cancertopics/pdq/screening/levels-of-evidence/HealthProfessio
nal